logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12487240 B1

PDFFull Text
Date of Patent:
Dec. 02, 2025

Filed:

Oct. 10, 2019

Tumor hla mutation versus matched normal hla

Applicant:

Nantomics, Llc, Culver City, CA (US);

Inventors:

John Zachary Sanborn, Culver City, CA (US);

Andrew Nguyen, Culver City, CA (US);

Assignee:

Nantomics, LLC, Culver City, CA (US);

Attorneys:

Umberg Zipser LLP

Martin Fessenmaier

Priti Phukan

Primary Examiner:

Cynthia B Wilder

Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 40/42 (2025.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56977 (2013.01); A61K 35/17 (2013.01); A61K 38/1774 (2013.01); A61K 39/0011 (2013.01); A61K 39/39558 (2013.01); A61K 40/4202 (2025.01); C12Q 1/6886 (2013.01); G01N 33/57492 (2013.01); G01N 33/6878 (2013.01); A61K 2039/523 (2013.01); A61K 2039/5256 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2570/00 (2013.01);
Abstract

Effectiveness of a neoepitope-based immunotherapeutic composition against a tumor can be increased by predicting the surface presentation of the neoepitope bound to the HLA molecule of the tumor cell. Surface presentation levels of neoepitopes can be predicted by identifying any changes in omics data of the tumor cell that may affect the expression or surface trafficking of the HLA molecule and that may affect binding affinities of neoepitopes to the HLA molecule.

Find Patent Forward Citations

Sanborn, John. (2025). Tumor hla mutation versus matched normal hla (U.S. Patent No. 12487240). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12487240

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…